Louis Navellier Announces Bold New Income Project

Louis Navellier just unveiled a radical new discovery — a way for Americans to earn 28-times more income than even the highest dividend-paying blue chip stocks.

5 Stocks With Crummy Sales Growth — RNA EXAS GNCA NBIX ALDR

The worst picks Portfolio Grader has to offer in this fundamental category

This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

RNA also gets F’s in Earnings Momentum and Equity. For more information, get Portfolio Grader’s complete analysis of RNA stock.

Exact Sciences Corporation (EXAS) is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. EXAS also gets an F in Equity. Since January 1, EXAS has fallen 67.3%. This is worse than the Nasdaq, which has remained flat. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

GNCA gets F’s in Analyst Earnings Revisions, Equity and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Neurocrine Biosciences, Inc. (NBIX) is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. NBIX gets F’s in Analyst Earnings Revisions and Equity as well. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

ALDR also gets F’s in Earnings Momentum and Analyst Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of ALDR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/10/5-stocks-with-crummy-sales-growth-rna-exas-gnca-nbix-aldr-rna-exas-gnca-2/.

©2020 InvestorPlace Media, LLC